Comparison of the efficacy of two potassium binders in the treatment of hyperkalaemia in patients with chronic kidney disease
10.3969/j.issn.1673-9701.2025.01.013
- VernacularTitle:两种钾结合剂治疗慢性肾脏病患者高钾血症的疗效比较
- Author:
Yuanmei YAN
1
;
Yu JIANG
;
Lusi MAI
;
Xin DENG
;
Huili CHANG
Author Information
1. 广州医科大学附属清远医院(清远市人民医院)药学部,广东 清远 511518
- Publication Type:Journal Article
- Keywords:
Chronic kidney disease;
Hyperkalemia;
Sodium zirconium cyclosilicate;
Calcium polystyrene sulphonate;
Efficacy;
Safety
- From:
China Modern Doctor
2025;63(1):54-57
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy and safety of sodium zirconium cyclosilicate and calcium polystyrene sulphonate in the treatment of hyperkalemia in chronic kidney disease(CKD).Methods Hospitalized patients with CKD hyperkalemia admitted to Qingyuan People's Hospital from January 2022 to November 2023 were retrospectively selected as study objects,and were divided into sodium zirconium cyclosilicate group and calcium polystyrene sulphonate group according to different drug use.The two groups of patients were matched with 1:1 propensity score,and finally 43 pairs of data were successfully matched.The efficacy and incidence of adverse reactions were compared between two groups of patients after matching.Results After treatment,the serum potassium level in both groups was significantly lower than that before treatment(P<0.05),but there was no significant difference in serum potassium level between two groups(P>0.05).There was no significant difference in the total effective rate between two groups(χ2=1.242,P=0.537).After treatment,the blood sodium level in sodium zirconium cyclosilicate group was significantly higher than that before treatment(P<0.05),there was no significant difference in blood calcium level before and after treatment(P>0.05).There was no significant difference in serum sodium and serum calcium before and after treatment in calcium polystyrene sulphonate group(P>0.05).There was one patient with hypokalemia in each group,and no treatment related adverse reactions such as nausea,edema,constipation,abdominal bloating and diarrhea were observed,and no abnormal laboratory test results were found.Conclusion The clinical efficacy of sodium zirconium cyclosilicate and calcium polystyrene sulphonate in treatment of hyperkalemia in CKD patients is comparable,and the safety is good.
